Kawasaki Fever - Causes, Treatment & When to See a Doctor

```html

What is Kawasaki Fever?

Kawasaki fever is the persistent high‑grade fever that characterises Kawasaki disease (KD), an acute vasculitis that mainly affects children under five years of age. The fever typically lasts ≥ 5 days and is often the first clue that a child is developing this potentially serious condition. Because the fever is usually accompanied by a constellation of other findings (skin rash, conjunctival injection, oral changes, extremity changes, and cervical lymphadenopathy), it is rarely seen in isolation. Recognising “Kawasaki fever” early is critical: untreated KD can lead to coronary artery aneurysms, the most significant long‑term complication.

Sources: Mayo Clinic, American Heart Association (AHA), National Institutes of Health (NIH).

Common Causes

While the exact trigger of Kawasaki disease remains unknown, several infectious, immunologic, and environmental factors are thought to precipitate the febrile inflammatory response. The following are the most frequently discussed potential contributors:

• Viral infections: adenovirus, Epstein–Barr virus, rhinovirus.
• Bacterial agents: Staphylococcus aureus, Streptococcus pyogenes, and atypical Mycoplasma pneumoniae.
• Superantigen‑producing toxins: toxins from Staphylococcus or Streptococcus that can trigger massive T‑cell activation.
• Genetic susceptibility: Polymorphisms in the ITPKC, CASP3, and FCGR2A genes increase risk.
• Environmental triggers: Seasonal patterns (winter‑spring peaks) suggest an environmental component.
• Immune dysregulation: Aberrant innate immune responses, especially involving cytokines such as IL‑6, TNF‑α, and IL‑1β.
• Airborne pollutants: Some epidemiologic studies link higher levels of particulate matter to increased KD incidence.
• Family history of vasculitis: Relatives with KD or other systemic vasculitides raise the likelihood.
• Vaccination timing: Rarely, fever following certain vaccines can mimic KD; however, vaccines do not cause true KD.
• Unknown triggers: In up to 30 % of cases, no identifiable precipitant is found.

These “causes” refer to factors that may set off the cascade leading to Kawasaki fever; they are not direct, single‑cause etiologies.

Associated Symptoms

Kawasaki fever is almost always part of a broader clinical picture. The classic diagnostic criteria (≥ 5 days of fever plus four of the five principal features) are:

• Conjunctival injection: Bilateral, non‑purulent redness of the eyes without crusting.
• Oral mucosal changes: Strawberry‑tongue, cracked lips, erythema of the oral cavity.
• Extremity changes: Swelling or erythema of the hands/feet during the acute phase, followed by peri‑ungual desquamation (peeling) in weeks 2‑3.
• Polymorphous rash: Usually non‑vesicular, can be maculopapular, erythema‑multiforme‑like, or scarlatiniform.
• Cervical lymphadenopathy: Unilateral node > 1.5 cm, often painful.

Extra‑cardiac manifestations that may appear include:

• Arthralgia or arthritis
• Gastrointestinal symptoms (vomiting, abdominal pain, diarrhea)
• Hepatomegaly or mild transaminitis
• Hydrocele in males
• Peripheral neuropathy (rare)

Because the disease can affect the coronary arteries, cardiac signs such as tachycardia, murmurs, or signs of heart failure may develop weeks after the fever resolves.

When to See a Doctor

Kawasaki fever is a medical emergency for children. Seek professional care promptly if any of the following occur:

• Fever ≥ 38.5 °C (101.3 °F) lasting 5 days or more without an obvious source.
• Red, bloodshot eyes without discharge.
• Bright red, cracked lips or a “strawberry” tongue.
• Unexplained rash that does not fade with antihistamines.
• Swollen, painful neck lymph node(s) larger than a grape.
• Swelling or redness of hands/feet, especially if accompanied by peeling.
• Any combination of the above plus irritability, reduced appetite, or lethargy.

Early evaluation reduces the risk of coronary artery aneurysms from > 25 % to < 5 % when treatment begins within the first 10 days of fever.

Diagnosis

Diagnosing Kawasaki fever relies on a careful clinical assessment; there is no single laboratory test that confirms KD. The typical work‑up includes:

Clinical criteria

1. Fever ≥ 5 days.
2. At least four of the five principal features listed above.
3. Exclusion of alternative diagnoses (e.g., streptococcal/pharyngitis, viral exanthems, drug reactions).

Laboratory studies

• Complete blood count – often shows leukocytosis with neutrophilia and normocytic anemia.
• Elevated acute‑phase reactants: C‑reactive protein (CRP) > 3 mg/dL, erythrocyte sedimentation rate (ESR) > 40 mm/h.
• Platelet count – typically rises after day 7 (thrombocytosis).
• Urine analysis – sterile pyuria is common.
• Liver enzymes – mild transaminitis in 30 % of cases.
• Serum electrolytes – hyponatremia may be present.

Imaging

• Echocardiography: First‑line cardiac imaging. It assesses coronary artery dimensions, detects aneurysms, and evaluates ventricular function. Recommended at diagnosis, at 2 weeks, and again at 6–8 weeks.
• Chest X‑ray: May show cardiomegaly or pulmonary congestion in severe cases.
• CT or MRI angiography: Reserved for unclear echocardiograms or when detailed coronary anatomy is needed.

Differential diagnosis

Physicians rule out conditions that mimic KD, such as scarlet fever, toxic shock syndrome, Stevens‑Johnson syndrome, viral exanthems (measles, adenovirus), and autoimmune diseases (systemic juvenile idiopathic arthritis).

Treatment Options

The cornerstone of therapy is to suppress inflammation quickly and protect the coronary arteries.

Intravenous immunoglobulin (IVIG)

• Dosage: 2 g/kg given as a single infusion over 10–12 hours.
• Effectiveness: Reduces fever within 24–48 hours in > 80 % of patients and dramatically lowers aneurysm risk.
• Adverse effects: Headache, aseptic meningitis, hemolysis, rare anaphylaxis (especially in patients with IgA deficiency).

Aspirin

• High‑dose phase: 30–50 mg/kg/day divided every 6 hours until the fever subsides.
• Low‑dose phase: 3–5 mg/kg/day continued for 6–8 weeks (or longer if coronary abnormalities persist) for antiplatelet effect.
• Monitor for Reye’s syndrome, especially in children who develop viral illnesses while on aspirin.

Corticosteroids

Used as adjunctive therapy for IVIG‑resistant KD (persistent fever 36 hours after completion of IVIG) or in patients at high risk for coronary complications. Prednisone 2 mg/kg/day tapered over 2–3 weeks is typical.

Biologic agents

• Infliximab: Anti‑TNF‑α monoclonal antibody, 5 mg/kg IV, shown to be effective in IVIG‑non‑responders.
• Anakinra: IL‑1 receptor antagonist, considered for refractory disease.
• Both require specialist consultation and close monitoring.

Supportive & home care

• Maintain adequate hydration; fever can cause increased insensible losses.
• Use acetaminophen for comfort if aspirin is contraindicated during the high‑dose phase.
• Encourage gentle activity; avoid strenuous exercise if coronary aneurysms are present.
• Observe skin lesions and keep them clean to prevent secondary infection.

Prevention Tips

Because KD’s exact cause is unknown, primary prevention is limited. However, the following measures may reduce the risk of infection‑related triggers and improve outcomes:

• Hand‑washing and routine hygiene to limit spread of common respiratory viruses.
• Timely vaccination according to the national schedule (influenza, COVID‑19, etc.) – vaccines do not cause KD but protect against infections that could act as triggers.
• Prompt treatment of streptococcal or staphylococcal infections to reduce superantigen exposure.
• Breastfeeding for the first 6 months, which provides immune protection against many viral agents.
• Avoid exposure to tobacco smoke and high‑pollution environments, which have been linked to higher KD incidence.
• If a child has a sibling or close relative with KD, discuss genetic counseling and close cardiac monitoring with a pediatric cardiologist.

Emergency Warning Signs

---

**References**

1. American Heart Association. 2020 Guidelines for the Diagnosis and Management of Kawasaki Disease. Circulation. 2020.
2. Mayo Clinic. Kawasaki disease. https://www.mayoclinic.org/diseases‑conditions/kawasaki-disease/
3. National Institute of Allergy and Infectious Diseases (NIAID). Kawasaki disease research. https://www.niaid.nih.gov/diseases‑conditions/kawasaki-disease
4. World Health Organization. Surveillance of Kawasaki disease. WHO Report, 2021.
5. Newburger JW, et al. "Kawasaki Disease." New England Journal of Medicine. 2022;386:1155‑1165.
6. Cleveland Clinic. Kawasaki disease – Symptoms, Treatment, & Prognosis. https://my.clevelandclinic.org/health/diseases/12603-kawasaki-disease

```